Recce (ASX:RCE) share price charges higher on COVID-19 update

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is pushing higher today after releasing an update on its COVID-19 studies…

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is pushing higher on Wednesday after the release of an announcement.

In morning trade the pharmaceutical company’s shares are up 4% to $1.12.

Why is the Recce share price pushing higher?

Investors have been buying the company’s shares this morning after it announced results from its international SARS-CoV-2 (COVID-19) in-vivo studies.

According to the release, the results demonstrate positive activity of RECCE 327 (R327) and RECCE 529 (R529) against the SARS-CoV-2 virus in Syrian golden hamsters.

The release explains that the study consisted of five groups of eight hamsters, each receiving a different treatment. These were a placebo control of saline nasal wash, a low dose of R327, a high dose of R327, a low dose of R529, and a high dose of R529.

All animals were infected with SARS CoV-2 on day zero, with treatments administered twice daily on days one to five.

The results, in both R327 and R529, demonstrated a positive reduction in COVID-19 viral load compared to the placebo group. On day four the low R529 dose achieved a log reduction in the order of 1.5 logs and the high dose of R327 achieved a log reduction of 1.25 logs.

However, two of the five hamsters with COVID-19 infection on day six indicated adverse clinical symptoms in the high dose R529 group and were excluded from the study. Though, management believes this is a study specific anomaly, because R529 was routinely well tolerated at considerably higher intravascularly infused doses in-vivo.

What now?

Management believes this hamster study is the first indication of the potential for nasal administration of its anti-infective compounds, specifically when used against viruses.

A gold-standard ferret COVID-19 study is underway in the United States seeking to build upon this method of administration. This includes higher dose concentrations and two other forms of administration, only possible in larger species. The data from this study is expected in early 2021.

Though, management has warned investors to not get too excited just yet. It commented: “Whilst Recce is delighted by the results, further testing must be completed before R327 or R529 are confirmed as being safe or effective against the SARS-CoV-2 virus.”

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A woman standing on a path flanked by big green trees is surrounded by colourful balloons tumbling from the sky.
Share Gainers

Why did the Pure Hydrogen share price pop 21% today?

Why did Pure Hydrogen shares have such an amazing day today?

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

Why Coronado Global, Lake, Megaport, and REA shares are storming higher

These ASX shares are having a good day...

Read more »

A girl runs along with her kite flying high in the sky.
Share Gainers

3 ASX mining shares rocketing by more than 20% today

Up we go in another day of double-digit gains for the ASX metals and mining equity bucket.

Read more »

Two men laughing while bouncing on bouncy balls
Share Gainers

Why is the BrainChip share price bouncing 6% higher today?

What's causing the BrainChip share price to pop on Tuesday?

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

Why is the Lake Resources share price powering up 17% today?

What's going on with the Lake Resources share price on Tuesday?

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Share Gainers

Why is the Incannex share price spiking 8% on Tuesday?

The stock has caught a bid on Tuesday.

Read more »

A little Asian girl is so excited by the bubbles coming out of her bubble machine.
Share Gainers

Why has the Redbubble share price burst 17% higher on Monday?

What pushed the e-commerce company's shares higher today?

Read more »

A cloud with a blue arrow pointing upwards through its middle symbolising a rising asx share price
Share Gainers

Guess which ASX tech share just soared 40% on takeover news

This small-cap ASX tech share has shot up 40% today.

Read more »